Literature DB >> 22496194

Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy.

L De Pasquale1, A D'Amico, M Verardo, S Petrini, E Bertini, F De Benedetti.   

Abstract

OBJECTIVES: Duchenne muscular dystrophy (DMD) is a degenerative muscle wasting disease caused by mutations in the dystrophin gene. Dystrophic muscle is characterized by chronic inflammation, and inflammatory mediators could be promising targets for innovative therapeutic interventions. We analyzed muscle biopsy samples of DMD-affected children to characterize interleukin (IL)-17 and Forkhead box P3 (Foxp3) expression levels and to identify possible correlations with clinical status.
METHODS: Expression levels of IL-17, Foxp3, tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), IL-6, and transforming growth factor-β (TGF-β) were analyzed by real-time PCR in muscle biopsy samples from patients with DMD (n = 27) and juvenile dermatomyositis (JDM) (n = 8). Motor outcome of patients with DMD was evaluated by North Star Ambulatory Assessment score.
RESULTS: In DMD, we found higher levels of IL-17 and lower levels of Foxp3 mRNA compared with those for a typical inflammatory myopathy, JDM. Moreover, the IL-17/Foxp3 ratio was higher in DMD than in JDM biopsy samples. IL-17 mRNA levels appeared to be related to the expression levels of other proinflammatory cytokines (TNF-α and MCP-1) and significantly associated with clinical outcome of patients.
CONCLUSIONS: The association of IL-17 expression with levels of other inflammatory cytokines and with the clinical course of DMD suggests a possible pathogenic role of IL-17.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496194      PMCID: PMC3335450          DOI: 10.1212/WNL.0b013e3182518302

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

3.  Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression.

Authors:  Mario Pescatori; Aldobrando Broccolini; Carlo Minetti; Enrico Bertini; Claudio Bruno; Adele D'amico; Camilla Bernardini; Massimiliano Mirabella; Gabriella Silvestri; Vincenzo Giglio; Anna Modoni; Marina Pedemonte; Giorgio Tasca; Giuliana Galluzzi; Eugenio Mercuri; Pietro A Tonali; Enzo Ricci
Journal:  FASEB J       Date:  2007-01-30       Impact factor: 5.191

Review 4.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

5.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

6.  Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A.

Authors:  Naoko Okiyama; Takahiko Sugihara; Yoichiro Iwakura; Hiroo Yokozeki; Nobuyuki Miyasaka; Hitoshi Kohsaka
Journal:  Arthritis Rheum       Date:  2009-08

7.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

8.  Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis.

Authors:  Gopal Murugaiyan; Akanksha Mittal; Howard L Weiner
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 9.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

View more
  22 in total

1.  D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity.

Authors:  Daniel P Reay; Sheldon I Bastacky; Kathryn E Wack; Donna B Stolz; Paul D Robbins; Paula R Clemens
Journal:  Mol Med       Date:  2015-05-22       Impact factor: 6.354

Review 2.  Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules.

Authors:  Mark G Rae; Dervla O'Malley
Journal:  J Neurophysiol       Date:  2016-07-06       Impact factor: 2.714

3.  Identification of Auxiliary Biomarkers and Description of the Immune Microenvironmental Characteristics in Duchenne Muscular Dystrophy by Bioinformatical Analysis and Experiment.

Authors:  Xu Han; Jingzhe Han; Ning Wang; Guang Ji; Ruoyi Guo; Jing Li; Hongran Wu; Shaojuan Ma; Pingping Fang; Xueqin Song
Journal:  Front Neurosci       Date:  2022-06-03       Impact factor: 5.152

Review 4.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

Review 5.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

6.  Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2.

Authors:  David P Burns; Leonie Canavan; Jane Rowland; Robin O'Flaherty; Molly Brannock; Sarah E Drummond; Dervla O'Malley; Deirdre Edge; Ken D O'Halloran
Journal:  J Physiol       Date:  2018-10-03       Impact factor: 5.182

Review 7.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 8.  Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy.

Authors:  Alicja Starosta; Patryk Konieczny
Journal:  Cell Mol Life Sci       Date:  2021-04-07       Impact factor: 9.261

9.  Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.

Authors:  Adonis Sfera; Carolina Osorio; Carlos M Zapata Martín Del Campo; Shaniah Pereida; Steve Maurer; Jose Campo Maldonado; Zisis Kozlakidis
Journal:  Front Cell Neurosci       Date:  2021-06-25       Impact factor: 5.505

Review 10.  p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.

Authors:  Christopher M Brennan; Charles P Emerson; Jane Owens; Nicolas Christoforou
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.